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TRANSIENT HYPERTROPHIC CARDIOMYOPATHY IN PREMATURE INFANTS
Eloisa V. Falzarano, Sharon E. O'Brien, William V. Tamborlane, Charles S. Kleinman,
and Alan H. Friedman, Department of Pediatrics, Yale University, New Haven, CT.
The purpose of this study is to examine whether iatrogenic hypertrophic
cardiomyopathy (HCM) in premature infants might be induced by routine neonatal
therapies including the administration of hyperalimentation, dexamethasone, and/or
insulin infusion. Infants with gestational age < 32 weeks and birth weight < 1250 grams
were studied. Echocardiographic and metabolic analyses were performed before 48
hours of age at enrollment, and again at one, two, three, and five weeks thereafter.
Eleven patients were studied with a median gestational age of 26 weeks (range
24-29 weeks) and median birth weight of 804 grams (range 609-1230 grams). All eleven
subjects received hyperalimentation, five received dexamethasone, and two received both
dexamethasone and an exogenous insulin infusion. The ratio of interventricular septal to
left ventricular posterior wall thickness increased significantly from 1.150.06 at
enrollment to 1 .5 10.06 (p<0.05) during the third week of life, consistent with the
diagnosis ofHCM. This ratio returned to a normal value of 1.170.1 by the fifth week of
life. C-peptide excreted in the urine peaked during the fourth week of life at 25399 ug/g
creatinine, and a peak in circulating insulin levels to 194 (iU/ml occurred during the
third week of life. Both the excreted C-peptide and circulating insulin levels decreased
by the end of the fifth week of life. All results are expressed as the meanSEM.
This preliminary data suggest that the development of a transient hypertrophic
cardiomyopathy occurs in premature infants, and appears to resolve as caloric intake,
insulin production, and circulating insulin levels decrease.
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Donald Teare was the first investigator to characterize the disease now known as
Hypertrophic Cardiomyopathy (HCM).1 In 1957, he described eight cases of
asymmetrical hypertrophy of the myocardium, or what he termed "benign tumor of the
heart", in a sub-group of people where sudden death and cardiac incapacity was rare.
The eight cases he described occurred in men and women between the ages of 14 and 44.
In three of the patients palpitation was the most striking early symptom that led to
medical examination, and all three were found to have atrial fibrillation and some degree
of heart failure. In addition, a history of "blackouts" was present in two cases.
Interestingly, the macroscopic and microscopic features of the myocardium in all cases
was virtually the same: the heart was marked by an overgrowth ofmuscle, particularly
prominent in the interventricular septum, which impinged on the ventricular aspect of the
mitral valve and lead to symptoms and signs ofmitral stenosis. The pathological picture
was one of bizarre and disorganized arrangement of muscle bundles associated with
hypertrophy of individual muscle fibers and their nuclei, with varying degrees of
fibrosis.1
Since Teare's initial description, the development of new technologies in the
fields of cardiology, genetics, and endocrinology, has led to an even greater
understanding of hypertrophic cardiomyopathy. HCM is now defined as a primary
myocardial abnormality where left ventricular and/or right ventricular hypertrophy of
unknown cause occurs. Unlike the generalized and concentric cardiac muscle
hypertrophy that occurs in response to an increase in afterload (such as in systemic
hypertension or aortic valve stenosis), the hypertrophy in HCM is usually asymmetrical
1
and associated with microscopic evidence ofmyocardial fiber disarray/ In addition to
the gross thickening of the ventricular wall, several histologic features have been
identified in the myocardium, including cardiac muscle-cell disorganization, myocardial
scarring, and abnormalities of the small intramural coronary arteries.
In HCM, characteristically it is the left ventricle which is hypertrophied to a
greater degree. The increase in left ventricular (LV) mass is due almost entirely to an
increase in the thickness of the ventricular wall. Within the left ventricle, the distribution
of hypertrophy is commonly also asymmetric and hypertrophy of the ventricular septum
is by far the most common type of asymmetric hypertrophy.2'3 The term asymmetric
septal hypertrophy (ASH) was originally used by Teare to describe the gross pathologic
appearance of the septum in patients with HCM.1 ASH refers to the disproportionate
hypertrophy of the septum compared to the posterior left ventricular wall.
One of the clinical and pathologic manifestations ofASH is known as Idiopathic
Hypertrophic Subaortic Stenosis (IHSS). By definition, IHSS is a type of subaortic
obstruction marked by the characteristic anatomic abnormality of asymmetric septal
hypertrophy.4 The pathology of subaortic obstruction is due to narrowing of the LV
outflow tract as a result of ventricular septal hypertrophy and the anterior displacement of
the papillary muscles and the anterior leaflet of the mitral valve.2 As the myocardium
contracts during systole, the mitral leaflets are "dragged" or pulled into the LV outflow
tract. The leaflets collapse against the hypertrophied septum and cause obstruction to
blood flow. This phenomenon is referred to as systolic anterior motion of the mitral
valve leaflets. In this report, we will use the term HCM to refer to abnormal thickening
2
of the myocardium, particularly of the septum, which may or may not be associated with
left ventricular outflow obstruction.
Transthoracic echocardiography and Doppler examination is undoubtedly the
most important form of laboratory investigation in hypertrophic cardiomyopathy. These
techniques can determine the location and extent of hypertrophy and the severity
obstruction. With echocardiography, asymmetric septal hypertrophy can be detected and
is characterized by a ventricular septum that is thicker than the posterior wall of the left
ventricle. Disproportionate ventricular hypertrophy in HCM is defined as the ratio of the
interventricular septal thickness to that of the posterior wall of the left ventricle
(IVS/LVPW) greater than 1.3: l5 and/or demonstrating ventricular wall thickness greater
than two standard deviations above the mean for gestational age . (Normally the
IVS/LVPW ratio approaches 1 :1 in healthy subjects.5) The detection ofASH by cardiac
echo represents the most specific and sensitive method available for diagnosing HCM.4
In addition to features of subaortic obstruction, diastolic dysfunction can also be a
characteristic of HCM due to decreased ventricular chamber compliance. The
disorganized and hypertrophied cardiac muscle cells lead to an increase in the stiffness of
the ventricular chamber which impairs muscle relaxation and ventricular filling during
diastole.1 Furthermore, myocardial ischemia has been repeatedly demonstrated in HCM
and may be related to small-vessel disease with decreased vasodilator capacity.




HCM has been shown to occur in adults, children, and neonates. Asymmetric
septal hypertrophy is the fundamental anatomic defect in HCM and its clinical spectrum
ranges from asymptomatic persons, to symptomatic patients without outflow obstruction,
and to severely limited patients with classical IHSS.4
The clinical course of HCM is variable, although the rate of progression of the
disease is believed to be more rapid in children, adolescents, and young adults. Left
ventricular hypertrophy is not always fully expressed at birth and may change markedly
in early life.3'7 Importantly, the morphologic expression ofHCM may not be complete,
or even appear until childhood and adolescence, when body growth, development, and
maturation are accelerated.8 Patients with obstructive HCM typically complain of
dyspnea, angina, and syncope on exertion. Congestive heart failure may be seen with
severe obstruction to outflow or severe systolic and/or diastolic dysfunction.
Sudden death is the most unpredictable and devastating complication of HCM and
occurs most commonly in young patients. Data suggest that the most common
precipitating factors of sudden death are cardiac arrhythmias, usually ventricular
tachycardia.2'3 Atrial and ventricular arrhythmias are an important feature of this disease
and are associated with significant morbidity and mortality. The annual mortality in
HCM is 4-6% in children and 3-4% in adults. HCM is the most common cause of
unexplained sudden death in otherwise apparently healthy athletes.2
HCM can present clinically during infancy with congestive heart failure and
cardiac enlargement, and can be a cause of infant death. In 1 974, Maron studied the
clinical features ofHCM specifically in the infant population.9 He described four infants
4
who each had marked hypertrophy of the ventricular septum which contained a
disordered arrangement of hypertrophied cardiac muscle. He concluded that the
characteristic pathologic feature of ASH in adults, a disproportionately thickened
ventricular septum containing numerous hypertrophied and disorganized cardiac muscle
cells, was present at birth.
In infants with HCM, unlike older children and adults with this condition, sudden
death is less common than death due to progressive congestive heart failure. Infants
with HCM probably suffer from impairment of ventricular filling due to the increased
number of cells and fibrosis of the myocardium, yielding a less compliant ventricle. '
This results in diastolic dysfunction and impaired relaxation of the ventricular muscle.
With higher filling pressures of the left ventricle and left atrium, pulmonary congestion
may result. The ensuing tachypnea makes feeding difficult for the infant, and poor
weight gain may result.
The Genetics ofHCM
In adults, HCM is unusual among the primary cardiac diseases in that it frequently
shows a familial pattern of inheritance. Genetic studies have demonstrated that HCM is
often transmitted in a pattern consistent with an autosomal dominant trait with variable
expression and penetrance. Recent advances in the field ofmolecular genetics have led
to the identification of the genes affected. At least 34 missense mutations have been
described in the B-myosin heavy chain gene on chromosome 14.2 In addition, mutations
in the cardiac troponin-T and the ot-tropomyosin genes have been described.2 The
hypertrophy in HCM may be compensatory in response to the abnormalities induced by
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these mutations.2 Echocardiographic studies have found that prevalence of the familial
form in only about 50 percent of cases, while approximately 45 percent of the cases of
HCM appear to be sporadic new mutations or may represent an acquired form of the
disease.3' 8
In the pediatric setting, HCM can occur in one of two contexts. In children and
adolescents it can be inherited as it is in the adult population. In neonates HCM also
occurs even in those with no family history ofHCM. In these latter cases it is
hypothesized that the development ofHCM may represent a new spontaneous mutation,
or, more commonly, it may be secondary to exposure to an abnormal metabolic
environment. Given the incidence ofHCM in neonates without a family history ofHCM,
several hypotheses, other than a genetic defect, have been offered to explain the origin of
the abnormal myocardial thickening observed in HCM. Investigators have suggested that
hypertension, catecholamines, glucocorticoids, and/or hyperinsulinemia may play a
causative role.
HCM andHyperinsulinemic States
Importantly, when HCM is discovered in infants, it must be distinguished from an
etiologically distinct, transient, and non-familial condition occurring in infants diabetic
mothers (IDM's). Like the genetic form ofHCM, this condition is characterized by
asymmetric septal hypertrophy, and may be associated with subaortic obstruction, and
heart failure.3 It is analogous to the adult form in that it can present with or without
clinical symptoms. Like the adult form ofHCM, arrhythmias and sudden death can
occur. However, what is most distinct about this form ofHCM seen in IDM's is that it is
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transient and resolves within the first few months of life. It is proposed that the
endogenous hyperinsulinemia induced in the infant of the diabetic mother produces
temporary myocardial hypertrophy which may progress to a fatal obstructive
cardiomyopathy."
It is known that infants born to diabetic mothers have a propensity to develop
cardiac disease. This high incidence of cardiovascular disease has been attributed to the
abnormal metabolic environment and abnormal hemodynamics of the diabetic mother.
However, a distinction must be made between the fetal abnormalities associated with
gestational diabetes (White's Class A) and those associated with long-standing insulin
dependent diabetes mellitus (such as White's Classes B, C, D, and E). (Refer to Appendix
A for a description ofWhite's Classification of diabetes in pregnancy.)
In a woman with previously diagnosed diabetes, maternal hyperglycemia occurs
during the first trimester during embryogenesis. It is hypothesized that exposure of the
first trimester embryo to abnormally high levels of glucose, as well as high levels of
ketones and free oxygen radicals may act as teratogens. These infants are known to
develop abnormalities of cardiovascular structure and anatomy, including complex heart
disease such as the conotruncal defects ( such as double outlet right ventricle, truncus
arteriosus, tetralogy of Fallot) and other cardiac defects. In addition, these children are
also at risk intra-uterine growth retardation due to placental vascular insufficiency, and
for other congenital malformations such as anencephaly, spina bifida, caudal regression
syndrome, absent kidneys, and tracheoesophageal fistula.
Alternatively, when hyperglycemia occurs in a woman with gestational diabetes,
it is a third trimester phenomenon, long after organogenesis is completed. In these
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fetuses, there is an association of hyperglycemia resulting in hyperinsulinemia, and
consequently the development ofmyocardial hypertrophy. These fetuses do not have a
high incidence of congenital abnormalities because they are not exposed to high levels of
glucose and other potentially teratogenic substances during the critical period of organ
formation in the first trimester.
The association of insulin excess with the development of HCM is well
recognized."'1 "' 14 Asymmetric septal hypertrophy was first observed in a stillborn
infant of a diabetic mother by Maron et al in 1974.9 In 1976, Gutgesell observed the
typical hemodynamic and echocardiographic features of hypertrophic subaortic stenosis
in three newborn infants.12 Interestingly, in these patients the left ventricular obstruction
resolved within the first six months of life. Family studies revealed no evidence of
familial cardiomyopathy. However, the mothers of two infants had insulin-dependent
diabetes mellitus and the mother of the third was presumed to be pre-diabetic, as
evidenced by impaired glucose tolerance. We now recognize this as gestational diabetes
mellitus.
Microscopically, the hypertrophic myocardial changes that have been noted in
these infants include not only hypertrophy and hyperplasia ofmyofibrils but also
disruption of the normal myofibrillar pattern, similar to that seen with familial HCM."
Subsequent investigators have confirmed that cardiac hypertrophy in the fetus and
newborn of the diabetic mother is not an uncommon occurrence. Veille examined 64
fetuses of diabetic mothers in utero and found that ventricular septal hypertrophy as
defined by two standard deviations above the mean was present in 75% of these fetuses.
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Sheehan15 studied a series of 20 infants of well-controlled diabetic mothers and found
that 35% exhibited exaggerated septal thickening.
In a second series of patients, Gutgesell examined the incidence and progression
of this cardiomyopathy in 47 infants of diabetic mothers.14 Twenty-four infants were
symptomatic, five had marked septal hypertrophy with echocardiographic features
suggesting left ventricular outflow obstruction, and one symptomatic infant died. These
abnormalities resolved within the first six months of life and the echocardiograms in first-
degree family members were normal. The results of this study confirmed that some
infants of diabetic mothers are susceptible to a unique, apparently transient, form of
hypertrophic cardiomyopathy. These results were also corroborated by Way in 1 979 who
studied the course ofHCM in infants of diabetic mothers. He confirmed that the natural
history is that of spontaneous regression of symptoms and septal hypertrophy.5
The echocardiographic, hemodynamic and histologic features of HCM in infants
of diabetic mothers are similar to those of familial HCM. However, the tendency for the
echocardiographic abnormalities to disappear within the first six months of life is unlike
the natural history of other forms ofHCM. The lack of asymmetric septal hypertrophy in
family members, and the tendency for the hypertrophy to decrease with time indicate that
the cardiomyopathy of IDM's has a different etiology than familial HCM.
Gutgesell hypothesized that the cardiac hypertrophy of IDM's could represent
another manifestation of their generalized organomegaly since these infants become
macrosomic as the excess glucose that passes transplacental^ is deposited under the
influence of excess fetal insulin.14 In addition, he proposed that fetal hyperinsulinemia
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would promote increased glycogen, lipid, and protein synthesis, with resultant obesity
and macrosomia.
For infants of diabetic mothers, there is a direct association between
hyperinsulinemia and macrosomia.13 It is known that blood glucose freely crosses the
placenta by facilitated diffusion, and therefore, fetal blood glucose reflects maternal
blood glucose levels. By this mechanism, chronic maternal hyperglycemia directly results
in fetal hyperglycemia. As elevation of blood glucose induces insulin secretion, a small
increase in maternal blood glucose may affect fetal pancreatic beta islet growth, leading
to fetal hyperinsulinemia. This is known as the Hyperglycemic Hypothesis which
proposes that the infants' pancreatic islets grow and secrete more insulin because they are
stimulated by small increments of blood glucose.16
Hypertrophy and hyperplasia of fetal islets as well as an increased content and
secretion of insulin are well documented in infants of diabetic mothers. Steinke looked at
the insulin content of the pancreas from fetuses and infants of diabetic mothers. He
found that the pancreases of the offspring of diabetic mothers contained more insulin than
the corresponding control group. Seven of the nine pancreases from the IDM's showed
typical marked hypertrophy and hyperplasia of the pancreatic islets. The insulin content
of fetal pancreases from infants of diabetic mothers as a group was markedly elevated.
The increased insulin content correlated with the histological picture of islet hypertrophy
and hyperplasia observed in infants of diabetic mothers. His results favor the
hyperglycemic hypothesis.
It has been shown that insulin has an important role specifically in the developing
fetal heart. James Steven demonstrated that plasma membranes of neonatal human and
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guinea pig myocardium are rich in insulin receptors.1 It is known that insulin plays a
significant role in fetal metabolism and growth by regulating glycogen, fat, and protein
synthesis which is responsible for the marked fetal growth during the third trimester. It
was initially believed that the increase in fetal insulin, in association with the high
number of insulin receptor sites led to increased protein, glycogen, and fat synthesis and
subsequent hyperplasia and hypertrophy ofmyocardial cells observed in large infants of
diabetic mothers. However, subsequent post-mortem studies in IDM's have
demonstrated that the myocardium is marked by a disorganized arrangement of cells
along with hyperplasia and fibrosis. It is not known how insulin influences the
myocardium to undergo these abnormal cellular changes. The sensitivity of the
myocardium to insulin is also supported by the fact that the cardiomegaly in the IDM's is
disproportionate to the enlargement of the other organs.
Breitweser hypothesized that fetal hyperinsulinemia contributes directly to the
septal hypertrophy and demonstrated that as the serum insulin level and number of
insulin receptors decrease following birth, septal hypertrophy regresses.1 In another
study, Nehgme examined the mechanism ofHCM in infants of diabetic mothers. He
demonstrated a direct effect of insulin on cell growth and division in cultured neonatal rat
ventricular myocytes manifested by increased cell surface area, protein content, and
protein synthesis.20 These observations suggest that fetal hyperinsulinemia is responsible
for HCM in the infant of the diabetic mother.
In addition to infants of diabetic mothers, other hyperinsulinemic, insulin-
sensitive states have been associated with excessive growth of cardiac muscle. For
example, infants with nesidioblastosis who have ductuloinsular cell proliferation with
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hyperplasia of the pancreatic islets can develop features ofHCM.13 Insulin-induced
cardiomyopathy has also been described in beta cell adenoma." Additionally, HCM has
also been noted in a number of insulin-resistant states. Children with leprechaunism who
have massive hyperinsulinemia, with insulin levels as much as one-hundred times
normal, have also been found to develop HCM.13 This condition results from a genetic
mutation that affects the number of function of insulin receptors. However, IGF- 1
receptors are structurally homologous to insulin receptors which may provide the
mechanism by which insulin could continue to promote tissue-specific growth of the
heart. Other insulin-resistant hyperinsulinemic disorders associated with ventricular
septal hypertrophy include lipodystrophy, acromegaly, and hypothyroidism.13
Dexamethasone and the Development ofHCM
The association of HCM with excess exposure to glucocorticoid is also well
established. ' ' Dexamethasone has been used in the treatment of ventilator-dependent
infants with bronchopulmonary dysplasia (BPD) to accelerate weaning from artificial
ventilation and to reduce pulmonary complications. The well-known side effects include
suppression of the hypothalamic-pituitary-adrenal axis, hypertension, catabolism, and
perforated gastrointestinal ulcers.
In 1993, Brand et al reported the occurrence of HCM in an another unexpected
population. The authors reported three infants who developed hypertrophic obstructive
cardiomyopathy during dexamethasone treatment for bronchopulmonary dysplasia.21
The Doppler tracings demonstrated muscular sub-valvular obstruction with a significant
pressure gradient in the left ventricular outflow tract. After discontinuation of
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dexamethasone therapy, septal and left posterior wall thickness decreased to normal.
Because the hypertrophic obstructive cardiomyopathy appeared and progressed during
dexamethasone therapy and resolved completely after its cessation. A causative
association between the hypertrophic cardiomyopathy and the exogenous glucocorticoid
therapy was inferred.
Since dexamethasone has no mineralocorticoid potency, a glucocorticoid effect is
proposed to be responsible for the development ofHCM. Glucocorticoids decrease
peripheral glucose utilization and stimulate gluconeogenesis, thus causing hyperglycemia
and reactive hyperinsulinemia. A reduced sensitivity to insulin-mediated cellular glucose
uptake leads to a rise in plasma glucose and hence to a compensatory stimulation on
insulin secretion in an attempt to normalize plasma glucose. Thus increasing insulin
resistance elicits a progressive rise in circulating insulin. Overt fasting hyperglycemia
finally develops when insulin resistance is severe and the compensatory insulin response
is exhausted. The anabolic properties of insulin could induce cardiac muscle
hypertrophy as has been described in the infants of diabetic mothers.
Werner also evaluated the potential induction of cardiac effects by high-dose
dexamethasone therapy.23 Again, the therapy was associated with a significant increase
in the thickness of the interventricular septum, diastolic left ventricular free wall, and
diastolic right ventricular free wall. These effects were transient, reached their maximal
degree by the third week of treatment, and approached pre-treatment conditions by the
sixth week of treatment. He concluded that a transient absolute myocardial hypertrophy
was associated with dexamethasone therapy in infants with bronchopulmonary
dysplasia.
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However, the relationship ofHCM to infants with BPD is further complicated. It
has been suggested that the onset of HCM could be related to the BPD itself, rather than
simply due to the effects of a particular metabolic environment. Left ventricular
hypertrophy is occasionally observed in infants with BPD, possibly due to increased
catecholamine synthesis as a result of recurrent hypoxemia."4 However, in Brand's
study, the clinical and radiologic signs ofBPD remained in the patients after the HCM
had resolved completely, making a causal association unlikely.21
In addition, arterial hypertension is a common side effect of glucocorticoids.
Hypertension, if present, could play an important role in the pathogenesis of HCM.24'25
Glucocorticoids have been associated with increased peripheral vascular resistance and
with diminished activity of vasodilating prostaglandins. However, Brand's patients had
normal blood pressure measurements throughout the course of dexamethasone.
' On the
other hand, Werner demonstrated that there was a transient increase in the heart rate and
mean arterial blood pressure of the infants treated with dexamethasone. However,
systemic hypertension is unlikely to be the sole cause of the myocardial hypertrophy
observed because the degree of hypertrophy was out of proportion to the extent of
elevation ofmean arterial pressure. In addition, Brand's infants had hypertrophy of both
the left and right ventricle, rather than isolated left ventricular hypertrophy, which
indicates that systemic hypertension unlikely as the sole cause of their observed HCM.21
Preliminary Data at Yale-New Haven Children 's Hospital
In 1995, the pediatric cardiology service at Yale-New Haven Children's Hospital
was consulted to evaluate two very-low-birth-weight premature infants for the presence
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of a patent ductus arteriosus. The initial echocardiographic assessment showed no
evidence of heart disease whatsoever, including normal myocardial wall thickness and
chamber dimensions. However, two weeks later, they were re-evaluated due to the
presence of newly recognized systolic heart murmurs. One of these patients had
symptoms of congestive heart failure. In both infants, the second echocardiogram
demonstrated the development of severe HCM with significant thickening of the septal
and ventricular walls. The infant with congestive heart failure had evidence of subaortic
obstruction. Neither infant had a family history ofHCM, nor were their mothers diabetic
during pregnancy. While exploring plausible etiologies, it was noted that the infants had
received high-calorie total parenteral nutrition (TPN) and had been on chronic insulin
infusion because they had been unable to maintain normal serum glucose levels. In
addition, one of these infants had received dexamethasone as therapy for chronic lung
disease.
As demonstrated in these two patients, standard medical management of the
premature infant often includes hyperalimentation to maximize caloric intake and
promote somatic growth. Exogenous insulin infusion may be required to maintain
euglycemia. In addition, dexamethasone therapy is frequently used to wean ventilatory
requirements and prevent chronic lung disease and which is common in premature
infants. The question posed was whether these therapies could be responsible for a post
natal environment characterized by elevated insulin levels. This would produce a
metabolic environment similar to that of the fetus of the diabetic mother and would lead
to the development of HCM.
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Statement of Purpose:
Based on established data and the preliminary data observed at Yale New-Haven
Children's Hospital, we proposed that routine management of the premature infant,
including high dose total parenteral nutrition, exogenous insulin infusion, and
dexamethasone therapy, could produce a metabolic environment characterized by
hyperinsulinemia. We hypothesized that hyperinsulinemia in the premature infant may
lead to the development ofhypertrophic cardiomyopathy. We further hypothesized that
normalizing the hyperinsulinemia will result in the resolution ofHCM in the premature
infant.
We designed a prospective experimental study in which all premature infants with
birth weights less than 1250 grams would receive metabolic and cardiovascular
evaluation before, during, and after routing neonatal management strategies are
undertaken.
The specific aims of this study were:
1. To quantify the circulating insulin levels during the first six weeks of life in the
premature infant who may be receiving hyperalimentation and/or insulin and/or
dexamethasone therapy.
2. To quantify ventricular structure, mass, systolic and diastolic function and wall stress
during the first six weeks of life in the premature infant who may be receiving
hyperalimentation and/or insulin and/or dexamethasone therapy.
3. To evaluate the relationship between glucose dosage, dexamethasone dosage, insulin





Inclusion criteria for study subjects included all premature infants admitted to the
Yale-New Haven Children's Hospital Newborn Special Care Unit with a gestational age
no greater than 32 weeks and a birth weight of 1250 grams or less. The infants were
enrolled within 48 hours following birth. Exclusion criteria included any congenital heart
disease other than normal fetal shunting pathways, such as patent ductus arteriosus and
patent foramen ovale. Infants with evidence of endocrinologic disease and infants born
to mothers with gestational or pre-gestational diabetes mellitus were also excluded.
Overview ofStudy Protocol
The length enrollment for each subject in the study was five weeks, or 35 days.
The study protocol included daily assessment of the subject's growth parameters, blood
pressure, caloric intake, types of feedings, medications, respiratory management, and
daily measurement of blood glucose by finger-stick technique. Interval assessment of
serum insulin levels as well as urinary C-peptide levels, were obtained on Days 0
(enrollment), 7, 14, 21, and 35. In addition, complete bedside echocardiographic
assessment was performed on study Days 0, 7, 14, 21, and 35.
Measurements
The data for this study was obtained in a prospective observational manner.
Maternal Parameters: At the time of enrollment, the study subject's mother was
interviewed by the research assistant in order to assess the pregnancy and birth history.
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Data collected included maternal age, gestational history, past medical history, significant
family medical history, and the use of any medications during the course pregnancy,
specifically glucocorticoids and beta agonists. In addition, the mother's metabolic history
during gestation was obtained, including the results of any glucose tolerance tests. A
Hemoglobin Ale level was analyzed immediately following enrollment as an indicator of
maternal glucose balance during the last three months of pregnancy.
Subject Data: At the time of enrollment, the subject's birth history was reviewed
by the research assistant, including Apgar scores, birth weight, body length, head
circumference, and assessments of gestational age by the estimated date of confinement
and by the physical exam. The administration of exogenous surfactant, if any, was noted.
Clinical Parameters: Detailed clinical monitoring and medical record review was
conducted and tabulated by the research assistant on a daily basis throughout the course
of the study. The parameters assessed included the subject's weight, heart rate,
respiratory rate, and blood pressure. The subject's ventilatory status was recorded,
including type of assisted mechanical ventilation, inspired oxygen concentration, and
arterial oxygen saturation. The volume and type of intravenous fluids administered was
recorded, with calculation of total calories provided over 24 hours, as well as the
concentration of glucose, lipids, and protein in the hyperalimentation solution. All drug
treatments were recorded, including the dose and number days of therapy of insulin
infusion and/or dexamethasone therapy.
Metabolic Parameters: At enrollment (Day 0) and on days 7, 14, 21, and 35, a
0.5 cc sample of blood was obtained from the subject and measured for glucose and
18
insulin. A urine sample was obtained to analyze the urinary excretion of C-peptide. a
byproduct of insulin metabolism.
Echocardiographic Evaluation: Each subject underwent a baseline
echocardiogram at enrollment, consisting of two-dimensional real-time imaging as well
as M-mode assessment, pulsed Doppler analysis and color Doppler mapping of flow
patterns. The investigator performing the evaluation was blinded as to the metabolic and
respiratory therapy provided to the subject. The echocardiographic parameters were
measured again throughout the course of the study on days 7, 14, 21, and 35 following
enrollment.
Specifically, the echocardiogram focused on measuring ventricular wall thickness,
the cavity dimensions of the left ventricle, and the flow dynamics of the left ventricle
across the mitral valve. The left ventricular mass, as well as the wall stress of the left
ventricle, was measured by standard two-dimensional and M-mode techniques. Other
indices of ventricular systolic function such as ejection fraction, shortening fraction as
well as indices of diastolic function such as peak E and A velocity, E to A ratio, and
isovolumetric relaxation time were measured and recorded. Doppler analysis was
performed to determine the presence and severity of obstruction to left ventricular
outflow, and to determine the stoke volume and the cardiac output in these patients.
Finally, color flow mapping was used to detect the presence of shunting at the level of the
ductus arteriosus and/or foramen ovale. (Refer to Appendix B for further definition of
the echocardiographic parameters measured in this study and the formulas used for
calculations.)
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Data Analysis: Statistical analysis was performed using ANOVA when
comparison of repeated measures over time were made. In addition, correlation
coefficients and multivariate analysis were performed. Since all premature infants by
definition are not healthy and are exposed to a variety of nutritional and medical
therapies, there were no "normal" controls. Therefore, subjects served as their own
controls, with the baseline values obtained at enrollment serving as control values. When
comparisons were made between subject groups, the Kruskal-Wallis test was used.
Measurements of cardiac structure and function were compared to normal values as
reported in the literature. Results are reported as the mean the standard error of the
mean unless otherwise stated.
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Results
From July 1996 through June 1997, fifteen patients were enrolled for the study
from the New Born Special Care Unit at Yale-New Haven Children's Hospital.
However, two infants were transferred out of Yale-New Haven Children's Hospital and
two died before the end of the study protocol. Table 1 shows the characteristics of the
subjects who participated in the study. A total of eleven patients completed the protocol
(3 male and 8 female) with a median birth weight of 804 grams (range of 609-1230
grams) and median gestational age of 26 weeks (range of 24-30 weeks). Three of the
mothers received perinatal steroids.
As a group, the infants in the study became relatively hyperinsulinemic by Day 14
of the study compared to baseline. Figure 1 shows that serum insulin levels increased
significantly from a baseline of 14.62.5 uU/ml to 18.33.1 uU/ml (p<0.05) by the end
of the second week of life. Resolution of the hyperinsulinemia occurred by Day 21, as
insulin levels returned to baseline and remained normalized until the end of the study
protocol. This suggests a relative hyperinsulinemia during the second to third weeks of
life. We also analyzed urinary C-peptide levels, in order to further assess the infants'
endogenous insulin production. Figure 2 shows a similar statistically significant increase
in the excreted urinary C-peptide from 127 33 ug/g creatinine on Day 0 to 242 71
|ag/g creatinine (p < 0.05) on Day 21. The peak in urinary C-peptide levels occurred one
week after the insulin peak.
Figure 3 demonstrates that for the group as a whole, there was a significant
increase in the ratio of the interventricular septal thickness to left ventricular posterior
wall thickness (IVS/LVPW) from a baseline value of 1.18 0.06 to 1 .37 0.07 by Day
14 of the protocol (p < 0.05). As a group, the infants met the criteria for the diagnosis of
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HCM, with an IVS/LVPW ratio >1 .3 : 1 . The development ofHCM was transient, and
resolved by Day 2 1 . These hypertrophic changes and their resolution correspond to the
hyperinsulinemia and its resolution.
However, not all of the subjects enrolled developed echocardiographic evidence
ofHCM. We then compared those subjects who developed HCM to those subjects who
did not develop the disease. Both groups had a normal IVS/LVPW ratio at enrollment,
however, seven of the eleven (64%) subjects had an IVS/LVPW ratio of 1 .5 1 : 1 during the
second week of life as is shown in Figure 4, meeting diagnostic criteria for HCM. One of
these subjects had symptoms of congestive heart failure, while the other six were
asymptomatic. In the HCM subgroup, the ratio returned to normal by the third week of
life, indicating the resolution ofHCM.
Figure 5 is an M-mode echocardiogram performed at enrollment (age 3 days).
The image reveals normal septal and posterior wall thickness and a normal IVS/LVPW
ratio. In contrast, Figure 6 demonstrates the marked hypertrophy of the septum without
concomitant change in the posterior wall, yielding a highly abnormal IVS/LVPW ratio.
This image representing HCM was obtained during the second week of life.
Interestingly, both groups of patients, those with HCM and those without HCM,
developed a relative hyperinsulinemia during the second week of life to levels of 19.9
4.4 and 17.0 4.8, respectively, as shown in Figure 7. However, there was no statistical
difference in the peak serum insulin levels between the two groups.
Several differences were noted when comparing the subjects who developed
HCM to those that did not. Table 2 shows that the subjects that were smallest and most
immature were those that did not tend to develop HCM. The subjects who developed
HCM tended to be gestationally more mature than those subjects who did not develop
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cardiac hypertrophy, with a mean gestational age of 27 0.8 weeks versus 25 0.4
weeks (p = 0.07). In addition, subjects with HCM had a mean birth weight of 868 66
grams compared to 690 50 grams (p = 0.10) in those who did not develop HCM.
Although these numbers were not statistically significant, they did show a trend toward
significance.
Therapies also differed among the subjects. While all subjects received nutrition
via hyperalimentation during the course of the study, two (18%) received dexamethasone
for chronic lung disease as well as exogenous insulin infusion for persistent
hyperglycemia. Five subjects (45%) received hyperalimentation and dexamethasone, and
four subjects (36%) received hyperalimentation alone. As the subject groups were
broken down by types of therapies received (ie hyperalimentation, exogenous insulin,
and/or dexamethasone), we looked at the percent change in thickness of the ventricular
septum from baseline. Figure 8 shows that although all three treatment groups
demonstrate a relative increase in myocardial thickness during week 2, the greatest
increase in IVS/LVPW thickness ratio occurred in the group of patients who received
hyperalimentation alone, from a baseline IVS/LVPW ratio of 1.04 0.78 at enrollment to
1.51 0.10 by Day 14 of life. This was followed by those who received both
hyperalimentation and dexamethasone (peak IVS/LVPW ratio of 1.20 0.10 at Day 14)
The smallest change in septal hypertrophy occurred in subjects who received all three
therapies (IVS/LVPW ratio of 1.33 0.12 at Day 14).
We also looked at the change in serum insulin levels based on the number and
types of therapies the study subjects received in the neonatal intensive care unit. Figure 9
shows that although all three groups had a relative increase in serum insulin levels at
week 2 over baseline at enrollment, the highest serum insulin levels were measured in the
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babies who received all three therapies. These infants had an increase in serum insulin
from 20.00 6.50 at baseline to a peak of 29.50 0.50 at Day 14. The subjects who
received both hyperalimentation and dexamethasone and subjects who received
hyperalimentation alone had insulin levels which were lower during the second week of
life (peak insulin levels of 15.25 4.88 and 29.50 0.50, respectively).
In order to assess myocardial function in patients with and without HCM, we
analyzed the ejection fraction and myocardial circumferential shortening fraction as
measured by bedside transthoracic echocardiography (See Appendix B). Table 3 shows
the trend in ejection fraction (EF), a measure of global systolic performance, during the
course of the study for both normal subjects and those who developed HCM. The values
for the EF at each stage of the study protocol were within normal limits (0.55-0.80) and
without much variability. In addition, neither group was significantly different from the
other. Table 4 shows the trend in circumferential shortening fraction. Again, in both
groups of subjects the circumferential shortening fraction remained within normal limits
throughout the course of the study (0.29-0.44), and the groups did not differ significantly
from each other.
Some prior studies have suggested that the use of dexamethasone in the treatment
of chronic lung disease in premature infants can cause systemic hypertension 24'25. We
measured daily blood pressured in all study subjects. No significant hypertension was
seen. In fact, only one infant had a blood pressure of 90 mm Hg at one isolated
measurement. All measurements for all other subjects were within normal limits
(considered to be a systolic pressure <90 mm Hg in the New Born Special Care Unit at
Yale-New Haven Children's Hospital). The data are shown in Figure 10. There was no
statistical significance in the blood pressures measured between the two groups.
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Table 1; Subject Characteristics





1 1 completed 3 male 804 26 3 mothers
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8 female 609-1230 24-30 hours of
(range) (range) delivery
Table 2: HCM Subgroup Characteristics
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Figure 1: Insulin Levels
25
p < 0.05
Figure 1: Serum insulin levels increased significantly by the end of the
second week of life to levels that were higher than at enrollment and than at
three and five weeks of life (study days 21 and 35, respectively)
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Figure 2: Excreted urinary C-peptide, a marker of endogenous insulin
production, increased by the end of the third week of life (Day 21). The levels
at Day 21 were significantly higher than at enrollment and than at Day 35 of
the study.
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Figure 3: There was a significant increase in the IVS/LVPW thickness ratio
by the end of the second week of life to a level that exceeded normal, meeting
the diagnosis ofHCM. This hypertrophy resolved by the third to fifth weeks
of life.
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Figure 4: Not all premature infants developed HCM. The subjects who
developed HCM had marked hypertrophic changes by the second week of life.










Figure 5: This is a representative M-mode echocardiogram from a subject at enrollment,
where A marks the thickness of the interventricular septum, B marks the dimensions of
the left ventricle, and C represents the thickness of the left ventricular posterior wall. In
this patient the interventricular septum measures 0.186 cm and the left ventricular









Figure 6: This is an M-mode echocardiogram a patient with HCM performed during the
second week of life. The interventricular septum measures 0.390 cm and the posterior
wall measures 0.203, with an abnormal IVS/LVPW of 1.92.
30






Figure 7: Both groups of subjects, those with HCM and those without HCM
appear to have a similar relative hyperinsulinemia during the second week of life.
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HA and Dex and Insulin
Figure 8: When broken down by types of therapies received, the greatest
increase in myocardial thickness from baseline occurred in the infants who
received hyperalimentation alone, followed by those infants who received both
hyperalimentation and dexamethasone. The smallest change in septal thickness
occurred in subjects who received all three therapies.
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Figure 9: Insulin Levels by Types of Therapies Received
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HA and Dex and Insulin
Figure 9: During week 2 of life, the highest peak levels of insulin were measured
in the infants who received all three therapies. The subjects who received both
hyperalimentation and dexamethasone and subjects who received
hyperalimentation alone had lower peak insulin levels during the second week of
life.
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Table #3: Ejection Fraction in Subjects With and Without HCM




0 0.68 0.03 0.71 0.04
7 0.77 0.03 0.80 0.04
14 0.8110.03 0.79 0.03
21 0.77 0.03 0.78 0.03
35 0.78 0.03 0.77 0.02
Table #4: Circumferential Shortening Fraction in Subjects With and Without HCM




0 0.35 0.02 0.36 0.03
7 0.42 0.02 0.46 0.05
14 0.47 0.03 0.45 0.03
21 0.43 0.03 0.43 0.03
35 0.44 0.02 0.41 0.02
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Figure 10: Sytolic Blood Pressure
Figure 10: In both groups of subjects, those with HCM and those without, the
systolic blood pressures remained less than 75 mm Hg throughout the duration of




Our study results demonstrate that premature infants are at significant risk for
developing hypertrophic cardiomyopathy. Sixty-four percent of the subjects who
completed our study protocol had echocardiographic evidence ofHCM. The observed
HCM was transient in nature, with resolution occurring uniformly by the third to fifth
weeks of life.
While the majority of infants met the criteria for HCM by echocardiography, most
remained asymptomatic and had normal measures of cardiac function (i.e. the ejection
and shortening fractions). One of the subjects had symptoms consistent with congestive
heart failure manifested by pulmonary edema and increased left atrial size with clinical
signs of decreased cardiac output. Another subject who did not complete the study
protocol died as a result of complications of prematurity (respiratory disease as well as
interventricular hemorrhage). However, an echocardiogram did demonstrate
hypertrophic chances consistent with HCM, in addition to diastolic dysfunction and
pulmonary vascular congestion. While this subject was not included in the data analysis,
this indicates that the HCM that develops in many of these premature infants may have a
significant clinical impact.
A similar case report that supports our data was published by Gill et al in 1996.
These authors reported two extremely low birth weight infants who developed HCM as
an iatrogenic complication of the concurrent therapeutic administration of glucocorticoid
and insulin. Both infants developed symptomatic cardiac changes associated with
marked myocardial hypertrophy, left ventricular outflow obstruction, and mitral valve
dysfunction. There was no family history ofHCM in either infant. As in our study, in
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both of Gill's patients the HCM resolved completely on cessation of therapy. The
authors postulated that insulin and dexamethasone acted synergistically to produce
myocardial changes and recommended caution when treating glucocorticoid-induced
hyperglycemia with insulin infusion, as the combination may induce a hypertrophic
obstructive cardiomyopathy.
Previous data have demonstrated that transient HCM can be a rare sequela of both
glucocorticoid and insulin excess.1 1'13,14'19'21'23 We propose that the hyperinsulinemia in
premature infants can produce hypertrophy and hyperplasia of immature myocardial cells
in a manner similar to the fetus of a diabetic mother. The three therapies we specifically
followed during the course of the study could all lead to hyperinsulinemia individually.
When these therapies are combined, as is common in these very sick infants, they may
act synergistically to induce hyperinsulinemia. Hyperalimentation, or total parenteral
nutrition, is extremely rich in glucose, as this is the main source of caloric intake for these
infants. High serum glucose levels directly stimulate pancreatic secretion of insulin, and
may lead to hyperinsulinemia. Dexamethasone, a glucocorticoid, is known to induce
peripheral insulin resistance and stimulate gluconeogenesis, and thereby lead again to
hyperglycemia and hyperinsulinemia. The third therapy we analyzed was the exogenous
infusion of insulin, a therapy which is employed when infants are not able to maintain
euglycemia with the high doses of glucose contained in their parenteral nutrition. It is
clear that an insulin infusion could in itself lead to high circulating levels of insulin, and
directly act on the myocardial cells to cause hypertrophy.
Our results show that there is a corresponding transient relative increase in serum
insulin levels in these premature infants that occurs during the second week of life. The
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rise and fall of insulin levels corresponds in onset and duration to the development of
HCM. This finding is analogous to the mechanism which explains the development of
HCM in the infant of the diabetic mother. As in infants of diabetic mothers, the relative
hyperinsulinemia in our subjects was transient and resolved by the third week of life.
It is interesting to note, however, that the relative increase in serum insulin levels
occurred in both the subgroup of infants who developed echocardiographic evidence of
HCM and those who did not develop HCM. This indicates that not all of our study
subjects were susceptible to developing the disease. We hypothesize that these results
indicate that there is a "window" of vulnerability in the myocardium of premature infants
during which it becomes susceptible to the anabolic and metabolic effects of insulin at a
particular stage of development. The subjects who developed HCM had an average
gestational age of 27 weeks, two full weeks greater than those subjects who did not
develop HCM. We propose that infants born at 24 to 25 weeks do not have a
developmentally vulnerable myocardium two weeks postnatally when the peak in insulin
levels occurs. Furthermore, we believe that HCM was not observed in these infants at
four to five weeks of age (gestational equivalent of 28 to 29 weeks) due to resolution of
the hyperinsulinemia. We believe that for HCM to develop in premature infants both
high levels of insulin and a developmentally vulnerable myocardium are necessary.
Therefore, our results indicate that although all premature infants become relatively
hyperinsulinemic, only those who fall within this time window will be vulnerable to
developing HCM.
Clinical experience at fetal cardiovascular centers suggests that the occurrence of
HCM in infants of diabetic mothers is a third trimester phenomenon, beginning on
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average between weeks 26 to 28 of gestation. This also coincides in time with the
development of the fetal pancreas and significant production of insulin which occurs
around the 20l week of gestation. HCM is not observed until the pancreas is
functional, since it has been well established that high levels of insulin are required for
myocardial hypertrophy to occur. These observations again correspond to the window of
time during which our study subjects developed HCM postnatally. Again, both for
premature infants and for the fetus of the diabetic mother, we believe that it is during this
time period that the myocardium is exposed to high circulating levels of insulin, resulting
in hypertrophy of the myocardium. Thus our observations support the theory of a
window of vulnerability when the developing myocardium is susceptible to the effects of
hyperinsulinemia.
Initially we expected that the hyperinsulinemic effects of the three therapies we
studied would be cumulative, that is the more therapies the infants received, the more
hyperinsulinemic they would become, and therefore, the greater the incidence of HCM.
However, this did not prove to be the case. While two of the eleven infants (18%)
received all three therapies (hyperalimentation, dexamethasone, and exogenous insulin
infusion), the change in septal thickness from baseline was actually less than in those
who received hyperalimentation alone or hyperalimentation as well as dexamethasone.
These two infants were among the smallest and gestationally immature of the study
subjects. In fact it was those infants who received only hyperalimentation who developed
the greatest change in thickness of the interventricular septum.
It is interesting to note, however, that the levels of relative hyperinsulinemia that
occurred during the second week of life did correlate with our initial hypothesis. While
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all three treatment groups showed a relative increase in insulin levels from baseline at
week two of life, it was the infants who received all three therapies (hyperalimentation,
dexamethasone, and insulin infusion) who had the highest peak levels of insulin. These
infants, however, had the lowest incidence ofHCM, as compared to the infants who
received only one or two of these therapies in the intensive care unit (hyperalimentation
and/or dexamethasone). However, the treatment groups were too small to allow for
statistically significant measurements.
In order to explain these findings, we propose that the infants who developed
HCM were a few weeks older in gestation, and therefore were a bit "healthier" than the
even younger and more developmentally immature premature infants who tended to be
more ill and require multiple therapies for survival. This again supports our theory that
HCM only develops if the premature myocardium is exposed to high levels of insulin
during a critical window of time during which it becomes vulnerable.
Prior investigators have reported an association between the development of
HCM in newborns with bronchopulmonary dysplasia (BPD) and treatment with
dexamethasone to accelerate ventilatory weaning. There are two issues to be dealt with.
The first is the issue of systemic hypertension as a cause of the myocardial hypertrophy
seen in patients with BPD, since glucocorticoids have been reported to lead to
hypertension. Greengough found a direct relationship between the use of
dexamethasone and an increase in systolic blood pressure in preterm infants with chronic
lung disease.24 However, both Brand21 and Werner23 studied the use of dexamethasone
in premature infants and found that a causal relationship was unlikely. The patients in
Brand's study had documented normal daily blood pressure measurements. In the
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Werner study, he found a transient increase in heart rate and mean arterial blood pressure
in premies treated with dexamethasone. However, Werner concluded that systemic
hypertension was unlikely to be the cause of the observed HCM as the hypertrophy of the
myocardium was felt to be out of proportion to the increase in blood pressure. Brand
speculated that glucocorticoids result in hyperglycemia and hyperinsulinemia, and that it
was this hyperinsulinemia which induced myocardial hypertrophy.
In our study, we followed daily blood pressure measurements in all subjects and
there was no evidence of hypertension, regardless of the use of corticosteroids. Only one
infant had a single daily systolic blood pressure greater that 90 mm Hg. Therefore, we
cannot invoke systemic hypertension as a mechanism of left ventricular hypertrophy in
these subjects.
Secondly, investigators have suggested that hypertension may be associated with
chronic lung disease itself, as hypoxia and hypercarbia lead to stimulation of arterial
chemoreceptors and lead to an increase in systemic vascular resistance. Again, our
patients had no evidence of developing hypertension. Moreover, in our study, HCM was
observed in both infants who developed BPD and those who did not, as well as those who
received dexamethasone and those who did not. In Brand's study, radiologic evidence of
BPD persisted after the discontinuation of dexamethasone, while the resolution of their
HCM corresponded in time to the discontinuation of the drug. Therefore, it seems
unlikely that the cause of the observed HCM can be attributed to chronic lung disease and
chronic hypoxia.
In conclusion, our results show that some premature infants develop a transient
acquired hypertrophic cardiomyopathy after birth. We believe that the metabolic
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environment of the premature infant is characterized by a period of transient
hyperinsulinemia. This, coupled with the vulnerability of the immature myocardium, can
lead to the development of HCM. We postulate that this process is analogous to the
mechanism ofHCM in the fetus of the diabetic woman. In both, high glucose levels lead
to high insulin levels, and in both groups, the HCM resolves with the resolution of the
hyperinsulinemia. The development ofHCM in premature infants can be asymptomatic,
or may lead to significant symptomatology including cardiopulmonary distress.
Further studies will focus on how the development of this hypertrophic
cardiomyopathy can be modulated, perhaps by altering current management practices in
the extremely premature infant and thereby decrease the occurrence ofHCM and its
subsequent morbidity and mortality. The findings of this study are previously unreported




White's Classification ofDiabetes in Pregnancy
(from the American College ofObstetrics and Gynecology, 1986)
Class A: Gestational Diabetes
Al: Requiring insulin
A2: Not requiring insulin
Class B: Diabetes of the adult. Onset after age 20, lasting < 10 years
Class C: Diabetes developing before age 20, or > 10 years duration
Class D: Diabetes developing before age 10, or > 20 years duration
Class E: Any age/duration, plus calcified limb or pelvic vessels
Class F: Any age/duration, plus nephropathy
Class R: Any age/duration, plus retinopathy
Class RF: Any age/duration, plus nephropathy and retinopathy
Class H: Any age/duration, plus atherosclerotic heart disease
Class T: Any age/duration, plus renal transplant
Appendix B: Definition of Echocardiographic Parameters
Ejection Fraction (EF):
This gives a global impression of LV function, and is calculated by measuring the
change in ventricular volumes between systole and diastole. It is stroke volume
divided by the total end-diastolic volume:
EF = (EDV - ESV)/EDV
Where EDV = end diastolic volume
ESV = end systolic volume
EDV - ESV = stroke volume
Measurements of distance are converted to estimates of volume (cm ) by the Tiecholz
modified formula:
Volume = (7.0 x D3)/(2.4 + D)
where D = measured chamber diameter
Normal values for infants are between 55% and 80%.
Circumferential Shortening Fraction of the LV (SF):
This represents a change in the LV diameter in the short axis that occurs with systole.
%SF = (LVDD - LVSD)/LVDD x 100
where LVDD = left ventricular diastolic dimension
LVSD = left ventricular systolic dimension
The normal mean value is 36%, and the normal range in children and adults is 28% to
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